Novartis Financial Results – Q3 2023
Novartis announced the company’s financial results for the third quarter of 2023.
Novartis executes separation of the Sandoz business to create an independent company by way of a 100% spin-off.
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
Novartis in Society Integrated Report 2022
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
Annual Report 2022
This report provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices and contains our operating and financial results, accompanied by audited annual financial statements.
Violence against innocent people runs counter to our work to improve human health
Novartis condemns all acts of terrorism and violence. Our thoughts are with all those affected by the tragic events that continue to unfold in Israel, Gaza and the West Bank.
Novartis provides support for Moroccan earthquake victims
Novartis is deeply concerned and saddened by the devastation caused by the earthquake in Morocco on September 9, 2023.
Novartis unwavering in support one year on from the start of the war in Ukraine
On February 24, we marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while our unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.